CoreCap Advisors’s Inhibrx INBX Stock Holding History

CoreCap Advisors’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18	Closed	-$252	–	2992
2025 Q1	$252	Buy	+18	New	+$244	﹤0.01%	2872

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CoreCap Advisors's INBX Position: Q2 2025 in Review

CoreCap Advisors sold out of Inhibrx (INBX) in Q2 2025, closing a stake of 18 shares — an estimated $252 sold.

CoreCap Advisors first reported a position in INBX in Q1 2025 and held it in 1 quarter. The position peaked at $252 in Q1 2025. 88 funds tracked by Wall St. Rank hold INBX as of Q2 2025.

CoreCap Advisors reported no remaining Inhibrx position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 18 Inhibrx shares in Q2 2025, an estimated $252.
CoreCap Advisors first reported a position in Inhibrx in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Inhibrx position peaked at $252 in Q1 2025.
88 funds tracked by Wall St. Rank held Inhibrx as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.